Eli Lilly (LLY) said the Australian Therapeutic Goods Administration granted marketing authorization for Kisunla, an injection for intravenous infusion given every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease.
An estimated 600,000 Australians are living with Alzheimer's, and 450,000 in the early stages could be evaluated to determine eligibility for treatment with Kisunla, or donanemab. the company said Wednesday in a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.